| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 10/31/2006 | US7129361 Thienylazolylalkoxyethanamines, their preparation and their application as medicaments |
| 10/31/2006 | US7129356 Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
| 10/31/2006 | US7129272 Apoptosis inhibitor |
| 10/31/2006 | US7129270 Antiinflammatory agents |
| 10/31/2006 | US7129258 Substituted benzoxazoles as estrogenic agents |
| 10/31/2006 | US7129256 Antiparkinsonism drugs |
| 10/31/2006 | US7129253 Compounds |
| 10/31/2006 | US7129250 Neuroprotective and anti-proliferative compounds |
| 10/31/2006 | US7129246 N-adamantlmethyl derivatives and intermediates as pharmaceutical compositions and processes for their preparation |
| 10/31/2006 | US7129243 Respiratory system disorders; cardiovascular disorders; antidiabetic agents; antiarthritic agents; antiinflammatory agents; immunosuppressants |
| 10/31/2006 | US7129242 Such as 4-((4-chlorophenyl)pyrimidin-2-yl)amino)benzamide; for treatment of inflammation/autoimmune conditions |
| 10/31/2006 | US7129241 Pyridazine derivatives |
| 10/31/2006 | US7129240 1,3-dihydro-2H-indol-2one derivatives, process for preparing them and pharmaceutical compositions containing them |
| 10/31/2006 | US7129237 5HT2c agonists or partial agonists; e.g., 4,5,6,7,9a,10,11,12,13,13a-decahydro-9H-(1,4)diazepino-(6,7,1 -de)phenanthridine hydrochloride |
| 10/31/2006 | US7129236 For therapy of immune related responses, tumor growth, glomerulonephritis, inflammation, malarial anemia, septic shock, tumor associated angiogenesis, vitreoretinopathy, psoriasis, graft versus host disease, atopic dermatitis |
| 10/31/2006 | US7129231 Regulation of intracellular glucocorticoid concentrations |
| 10/31/2006 | US7129228 Heterocyclic analgesic compounds and methods of use thereof |
| 10/31/2006 | US7129213 Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases |
| 10/31/2006 | US7129207 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of cancer, psoriasis and nervous system disorders |
| 10/31/2006 | US7129077 Gene expression inhibition; solid phase synthesis; drug screening; for treating cancer, central nervous system disorders, and chronic obstructive pulmonary disorder |
| 10/31/2006 | US7129073 Regulation of neuronal function through metabotropic glutamate receptor signaling pathways |
| 10/31/2006 | US7129065 bHLH-PAS proteins, genes thereof and utilization of the same |
| 10/31/2006 | US7129064 Canine hepatocyte growth factor |
| 10/31/2006 | US7129034 Culturing stem cell with fibroblast growth factor and epidermal growth factor |
| 10/31/2006 | CA2383599C Methods, kits and compositions for using pyrrole derivatives |
| 10/31/2006 | CA2355886C Substituted oximes and hydrazones as neurokinin antagonists |
| 10/31/2006 | CA2350560C Novel type condensed pyridazinone compounds |
| 10/31/2006 | CA2333405C Spill resistant pharmaceutical compositions |
| 10/31/2006 | CA2246126C New piperazine compounds |
| 10/31/2006 | CA2193096C Guanylic acid derivatives and their use as drugs |
| 10/26/2006 | WO2006113864A2 Oxindole compounds and their uses as therapeutic agents |
| 10/26/2006 | WO2006113853A2 Topiramate compositions for treatment of headache |
| 10/26/2006 | WO2006113448A1 Pharmacological treatment for sleep apnea |
| 10/26/2006 | WO2006112744A2 Drug composition with analgesic, anti-inflammatory and decongestive activity |
| 10/26/2006 | WO2006112551A2 A THERAPEUTIC AGENT FOR Aβ RELATED DISORDERS |
| 10/26/2006 | WO2006112550A2 A THERAPEUTIC AGENT FOR Aβ RELATED DISORDERS |
| 10/26/2006 | WO2006112464A1 Piperazine-substituted benzothiophenes for treatment of mental disorders |
| 10/26/2006 | WO2006112456A1 Perkinson disease-related gene grk5 and use thereof |
| 10/26/2006 | WO2006112449A1 NOVEL NON-HUMAN ANIMAL MODEL FOR ALZHEIMER'S DISEASE HAVING DETERIORATED A-β EXCRETION FUNCTION |
| 10/26/2006 | WO2006112334A1 Sedative effect-providing agent and sedative fragrance composition containing the same |
| 10/26/2006 | WO2006112331A1 Novel condensed pyrrole derivative |
| 10/26/2006 | WO2006112313A1 Protective agent for retinal neuronal cell comprising indazole derivative as active ingredient |
| 10/26/2006 | WO2006112276A1 Propofol-containing fat emulsion |
| 10/26/2006 | WO2006111833A1 Functional herbal cigarette in controlling body weight and composition |
| 10/26/2006 | WO2006111653A1 Use of agomelatine for obtaining medicaments used for treating bipolar disorders |
| 10/26/2006 | WO2006111517A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| 10/26/2006 | WO2006111424A1 Methods for identifying modulators of cb1 and cb2 cannabinoid receptors and their use in wound healing |
| 10/26/2006 | WO2006111348A1 Use of heparin and heparin derivatives for modulating the neurite growth-controlling nogo receptor |
| 10/26/2006 | WO2006111103A1 Functions and uses of gpr39 gene in mammalian central nervous system |
| 10/26/2006 | WO2006111085A1 A method, formulation and use thereor with improved oral absorption of drugs or nutrients |
| 10/26/2006 | WO2006075004A3 3, 8 - substituted 8-aza-bicyclo[3.2.1] octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 10/26/2006 | WO2002101008A3 Intracellular signaling molecules |
| 10/26/2006 | US20060242716 Disease model animal carrying foreign ppar alpha gene transferred thereinto and use thereof |
| 10/26/2006 | US20060241320 Rapidly cooling a solution of modafinil in a solvent other than ethanol and filtering the crystals formed; treatment of diseases such as sleep disorders, CNS disorders, ADHD, depression, eating disorders and seasonal affective disorders |
| 10/26/2006 | US20060241302 Morpholine derivatives |
| 10/26/2006 | US20060241299 Process for making spirolactone compounds |
| 10/26/2006 | US20060241284 Transmembrane protein amigo and uses thereof |
| 10/26/2006 | US20060241189 Sertraline hydrochloride polymorphs |
| 10/26/2006 | US20060241188 Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors |
| 10/26/2006 | US20060241181 Alpha-ketoglutarates of active ingredients and compositions containing same |
| 10/26/2006 | US20060241179 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors |
| 10/26/2006 | US20060241169 Crystalline forms of [R-(R*.R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1) |
| 10/26/2006 | US20060241168 administering a protein kinase B activating agent comprising (R)-5,6-dimethoxy-2-[2,2,4,6,7-pentamethyl-3-(4-methylphenyl)-2,3-dihydro-1-benzofuran-5-yl]isoindoline; treating depression, posttraumatic stress disorder, Parkinson's disease, Alzheimer's diseases |
| 10/26/2006 | US20060241143 Combination of paroxetine and 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenyl-piperidin-3s-yl)-amine for treatment of depression and/or anxiety |
| 10/26/2006 | US20060241142 Naphthamide derivatives and their use |
| 10/26/2006 | US20060241141 Use of pyridin-2-ylmethylamine derivatives for the production of a medicament for the treatment of chronic pain symptoms of neuropathological or psychogenic origin |
| 10/26/2006 | US20060241137 Triazole compounds and the therapeutic use thereof |
| 10/26/2006 | US20060241133 Electrically variable pneumatic structural element |
| 10/26/2006 | US20060241132 Spiro derivatives and adhesion molecule inhibitors comprising the same as active ingredient |
| 10/26/2006 | US20060241131 Pyrrolo[2,3-d]pyrimidine compounds |
| 10/26/2006 | US20060241126 Phospholipase inhibitors perticularly phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2; N-(1-Methylpiperidin-4-yl)-(2-(2-(2,3-difluorophenyl)ethyl)-4-oxo-4H-pyrido[2,3-d]pyrimidin-1-yl)-N-(4-(4-trifluoromethylphenyl)phenyl)methylacetamide; amidation |
| 10/26/2006 | US20060241124 Combinations comprising paroxetine and 2- (s) - (4-fluoro-2-methyl-phenyl) -piperazine-1-carboxylic acid [1- (r)- (3,5-bis-trifluoro-2-methyl-phenyl) -ethyl]-methyl amide for treatment of depression and/or anxiety |
| 10/26/2006 | US20060241123 Substituted piperidine and piperazine derivatives as melanocortin-4 receptor modulators |
| 10/26/2006 | US20060241116 affinity for peripheral-type benzodiazepine receptors; in vitro and in vivo affinity; chemical intermediates |
| 10/26/2006 | US20060241102 Medicinal compositions |
| 10/26/2006 | US20060241101 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
| 10/26/2006 | US20060241096 Agent for preventing or treating organ functional disorders and organ dysfunction |
| 10/26/2006 | US20060241085 Compounds having anti-proliferative properties |
| 10/26/2006 | US20060241051 Metastin derivatives and use thereof |
| 10/26/2006 | US20060241046 Peptide for use in the treatment of parasitic, brain, nervous system, psychological and viral disorders |
| 10/26/2006 | US20060241021 Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| 10/26/2006 | US20060240520 monitoring the efficacy of a BAFF-R (a B-cell activating factor belonging to the Tumor Necrosis Factor family) antagonist in the treatment of a disease or disorder associated with aberrant levels of B-cells or B-cell activity |
| 10/26/2006 | US20060240519 Novel receptor nucleic acids and polypeptides |
| 10/26/2006 | US20060240518 polypeptides related to a receptor to BAFF (a B-cell activating factor belonging to the Tumor Necrosis Factor family, which is associated with theexpression of B-cells and immunoglobulins); this receptor can be employed in the treatment of cancers, lymphomas, autoimmune diseases related to B-cells |
| 10/26/2006 | US20060240517 Novel receptor nucleic acids and polypeptides |
| 10/26/2006 | US20060240465 CNG2B: a novel human cyclic nucleotide-gated ion channel |
| 10/26/2006 | US20060240432 Transmembrane serine protease probes for use as evaluative tool in detection of nervous system stem cells and treatment of neurodegenerative diseases; regenerative medicine; tissue engineering |
| 10/26/2006 | US20060240127 Use of agomelatine in obtaining medicaments intended for the treatment of bipolar disorders |
| 10/26/2006 | US20060240050 Stable clozapine suspension formulation |
| 10/26/2006 | US20060240023 Apoptosis-associated protein and use thereof |
| 10/26/2006 | US20060240013 Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37) |
| 10/26/2006 | US20060240010 Methods of modulating CD200 receptors |
| 10/26/2006 | US20060240004 Methods for treating tweak-related conditions |
| 10/26/2006 | US20060239997 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| 10/26/2006 | US20060239993 Containing a mutant angiotensin-converting enzyme that releases glycosylphosphatidylinositol-anchored protein from cell surfaces; for treating a prion-related disease, a bacterial infectious disease or male infertility due to sperm-egg binding insufficiency |
| 10/26/2006 | US20060239936 Delivery of anti-migraine compounds through an inhalation route |
| 10/26/2006 | US20060237004 Methods for treating trigeminal neuralgia |
| 10/26/2006 | US20060237003 Methods for treating headaches |
| 10/26/2006 | DE102005020105A1 New thiazolidinone compounds are polo-like kinase inhibitors, useful for the preparation of medicament to treat e.g. cancer, autoimmune disease, cardiovascular disease stenosis and infection disease |
| 10/26/2006 | DE102005020104A1 New thiazolidinone compounds are polo-like kinase inhibitors, useful for the preparation of medicament to treat e.g. cancer, autoimmune disease, cardiovascular disease stenosis and infection disease |